Could CSF1R expression be used as a prognostic biomarker in #GastricCancer? 🧬

@kyosuke_seguchi at #ESMOGI26 explores findings from MONSTAR-SCREEN-2 investigating this 🧪🔬

Watch:

#Oncology #CTSM #STCsm @myESMO

This video is available on the GI Cancer

Could CSF1R expression be used as a prognostic biomarker in gastric cancer?

Kyosuke Seguchi, MD, Kameda Medical Center, Kamogawa, Japan, discusses the further validation that needs to occur befo...

ow.ly

At #ASCO26, @FilippoPietran4 explores results from a Phase III trial of trastuzumab rezetecan vs SOC in HER2+ advanced #CRC 💉

The drug demonstrated significantly prolonged #PFS, improved #ORR and a manageable safety profile 📈

Watch:

#Oncology

Phase III trial of trastuzumab rezetecan vs SOC in HER2-positive advanced CRC

Filippo Pietrantonio, MD, Fonzdazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, highlights results from a Phase...

ow.ly

Wungki Park (@CentralParkWMD) at #ESMOGI26 explores findings from the POLAR trial evaluating pembrolizumab and olaparib in HRD metastatic #PancreaticCancer 🧬

Patients with core HRD mutations showed improved #PFS and #ORR 📈 💪

Watch:

#Oncology

POLAR: pembrolizumab and olaparib in HRD metastatic pancreatic cancer

Wungki Park, MD, MS, Memorial Sloan Kettering Cancer Center explores background and findings from the Phase II POLAR...

ow.ly

Yu Tanaka at #ASCO26 explores findings from the LC-SCRUM-Asia study evaluating T-DXd efficacy in #HER2 exon 20 insertion-positive #NSCLC, stratified by prior #HER2 TKI exposure 🧬 🫁

Watch:

#Oncology #TrialUpdate #LCSM #ImmunoOnc @ASCO

This video is

T-DXd after HER2-TKI exposure in HER2 exon 20 insertion-positive NSCLC

Yu Tanaka, MD, PhD, National Cancer Center Hospital East, Tokyo, Japan, explores data from the LC-SCRUM-Asia study e...

ow.ly

In a recent interview at #ESMOGI26, @RamonSalazarS explores primary tumor resection for local symptom management in patients with #mCRC 🏥🥼

Watch:

#Oncology #ColorectalCancer #CRCSM #SurgOnc @myESMO

This video is available on the GI Cancer Channel on

Primary tumor resection for local symptom management in patients with mCRC

Ramon Salazar, MD, PhD, Institut Catala D’Oncologia, Barcelona, Spain, discusses primary tumor resection in patients w...

ow.ly